THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS

In Section A, participants will obtain distinct doses and schedules of oral ABBV-744 tablet to detect Harmless dosing routine. Further participants will be enrolled at the recognized monotherapy dosign program. In Section B, contributors will get oral ruxolitinib and ABBV-744 will likely be offered as "add-on" therapy. In Section C, participants wi